Get the Stockscreener App
27.25
1.49%
0.40
After Hours:
27.25
Rapport Therapeutics Inc stock is traded at $27.25, with a volume of 468.36K.
It is up +1.49% in the last 24 hours and up +1.76% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$26.85
Open:
$26.61
24h Volume:
468.36K
Relative Volume:
0.58
Market Cap:
$1.30B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.82%
1M Performance:
+1.76%
6M Performance:
+171.41%
1Y Performance:
+21.00%
1-Day Range:
$26.05
$28.29
1-Week Range:
$23.75
$29.10
52-Week Range:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
27.25 | 1.28B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
(RAPP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can Rapport Therapeutics Inc. stock outperform in 2025 bull marketStop Loss & Long-Term Growth Stock Strategies - newser.com
Can trapped investors hope for a rebound in Rapport Therapeutics Inc. - newser.com
What institutional flow reveals about Rapport Therapeutics Inc.Weekly Stock Analysis & Daily Entry Point Trade Alerts - newser.com
Will Rapport Therapeutics Inc. stock pay special dividendsJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyzing Rapport Therapeutics Inc. with risk reward ratio chartsTreasury Yields & Safe Capital Growth Tips - newser.com
BTIG Research Initiates Coverage on Rapport Therapeutics With Buy Rating, $47 Price Target - MarketScreener
BTIG Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - Nasdaq
What candlestick patterns are forming on Rapport Therapeutics Inc.Gap Up & Verified Entry Point Signals - newser.com
Why Rapport Therapeutics Inc. stock is a value investor pick2025 Technical Overview & Technical Pattern Based Signals - newser.com
Published on: 2025-11-18 22:13:16 - newser.com
Tools to monitor Rapport Therapeutics Inc. recovery probabilityMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
Rapport Therapeutics Executives Sell Shares Under Trading Plans - TradingView
CEO Ceesay Sells 10,916 ($275K) Of Rapport Therapeutics Inc [RAPP] - TradingView
Rapport Therapeutics, Inc. (RAPP) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is Rapport Therapeutics Inc a good long term investmentHigh Yield Income Stocks & Predict Price Movements With AI Precision - earlytimes.in
Rapport Therapeutics, Inc. (RAPP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
H.C. Wainwright Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
What analysts say about Rapport Therapeutics Inc stockShort Interest Overview & Small Capital Trading Tips - earlytimes.in
What Analyst Expectations Mean for Mahaan Foods Limited Stock Volatility - earlytimes.in
What Makes Poddar Housing and Development Limited a Resilient Investment During CrisesPrice-to-Earnings Ratio Insights & Small Investment Capital Tips - earlytimes.in
Can Kross Limited Maintain Its Share of Global Market for Its ProductPortfolio Risk Assessment & Let Our AI Be Your Trading Assistant - earlytimes.in
Will Rapport Therapeutics Inc. stock benefit from automationJuly 2025 Big Picture & Expert Verified Stock Movement Alerts - Fundação Cultural do Pará
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):